Lin L, Gui YZ, Lu X, Chen J, Lu Q, Min M, Jing XR, Yao L. Role of contrast-enhanced ultrasound in assessing short-term therapeutic response to high-intensity focused ultrasound in patients with pancreatic carcinoma.
Shijie Huaren Xiaohua Zazhi 2011;
19:196-199. [DOI:
10.11569/wcjd.v19.i2.196]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the role of contrast-enhanced ultrasound (CEUS) in assessing the short-term therapeutic response to high-intensity focused ultrasound (HIFU) in patients with pancreatic carcinoma.
METHODS: Twenty-nine patients with pancreatic carcinoma received HIFU treatment. CEUS was performed to monitor the response of tumor vessels to HIFU ablation before and after treatment. Meanwhile, 15 patients underwent magnetic resonance imaging (MRI) for comparison.
RESULTS: Before treatment, hypoenhancement was found on CEUS in 23 (79.3%) patients, and isoenhancement to hyperenhancement in 6 (20.7%) patients. Contrast agent washout was significantly faster in pancreatic carcinoma lesions than in normal pancreatic tissue in all cases. Complete non-enhancement area was noted in 8 cases after first HIFU therapy, in 12 cases after second therapy, and in 4 cases after third treatment. Five cases presented hypoenhancement at the boundary of the lesion even after third treatment and needed more treatments. The accuracy of CEUS was similar to that of MRI in assessing the response to HIFU therapy (86.7% vs 93.3 %, P > 0.05).
CONCLUSION: CEUS allows to accurately differentiate tumor necrosis and evaluate response to HIFU treatment in patients with pancreatic carcinoma.
Collapse